Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
NCT ID NCT03662074
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This phase II pilot trial is asking whether combining the chemotherapy drug gemcitabine with the immunotherapy drug nivolumab can shrink tumors in people with advanced small cell lung cancer that has spread and no longer responds to initial treatment. The study enrolls about 14 adults who have already had platinum-based chemotherapy. Researchers will measure how many participants see their tumors shrink and how long they live, comparing the results to a historical benchmark to see if the combo is worth pursuing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine and nivolumab
- What this could lead to
- If this combination works, it could offer a new treatment option for people with advanced small cell lung cancer who have run out of standard therapies.
- What could go wrong
- This is a small pilot study, so results may not apply broadly. The combination may not shrink tumors enough to be better than existing options, and both drugs can cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can head radiation stop lung cancer from spreading to the brain?
- Wheat germ supplement studied for immune boost in advanced cancer
- New hope for tough lung cancer: drug plus radiation combo shows promise in early trial
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy